L
LPCN
Lipocine Inc
3.15
0.05+1.61%Closed15:59 12/05 EST
OPEN/PREV CLOSE3.140/3.100
TODAY RANGE3.140-3.310
VOL26.31K
MARKET CAP17.49M
52 WEEK RANGE2.520-5.50
AVG VOL (3M)43.12K
% TURNOVER0.47%
TURNOVER--
P/E (TTM)-3.0408
% RANGE5.48%
EPS(TTM)-1.0359
P/E(FORWARD)-1.6031
P/B1.207
BVPS2.609
DIVIDEND--
P/S1.504
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP16.99M
SHARES OUTSTANDING5.55M
NEXT EARNINGS03/11-03/16
FREE FLOAT5.39M
LOT SIZE1
EX-DATE05/12/2023
News
Press Releases
Financial Reports
Profile
TipRanks·11/18 14:58
Lipocine Announces Positive Interim Results for PPD Trial
TipRanks·11/18 14:58
Lipocine Updates Corporate Presentation for Investors
TipRanks·11/18 14:44
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154
Reuters·11/18 13:00
LIPOCINE INC - NO DOSE REDUCTIONS OR DRUG-RELATED SAES REPORTED
Dow Jones·11/13 13:04
Lipocine Is Maintained at Buy by HC Wainwright & Co.
Dow Jones·11/13 13:04
Lipocine Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co.
Benzinga·11/13 12:55
HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7
TipRanks·11/13 11:37
Lipocine (LPCN) Receives a Buy from H.C. Wainwright
TipRanks·11/13 11:20
Lipocine price target lowered to $7 from $8 at H.C. Wainwright
TipRanks·11/07 20:55
Lipocine (LPCN) Gets a Buy from Alliance Global Partners
NASDAQ·11/06 14:10
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Seeking Alpha·11/06 13:27
Lipocine GAAP EPS of -$0.59 misses by $0.05
Reuters·11/06 13:08
Biopharma firm Lipocine's Q3 net loss widens
Same Industry
Name/Symbol
Change%
Price